Orexo invites to a Zubsolv™ (OX219) information meeting on September 21 in Stockholm
Uppsala, September 17, 2012 – Orexo today announces the invitation of analysts, investors and media to an information meeting about Zubsolv™ (OX219), a product developed for treatment of opioid dependence, this coming Friday September 21.
Date: Friday, September 21 2012
Time: 10:00am-1:00pm (lunch included)
Place: ABG, Sundal Collier AB, Regeringsgatan 65, 5 floor, Stockholm
RSVP: registration ASAP to email@example.com
As previously announced, Orexo submitted on September 5 a New Drug Application (NDA) to the FDA for Zubsolv™ (OX219), a novel combination product of buprenorphine and naloxone for treatment of opioid dependence, 5 months ahead of schedule. Opioid dependence is today affecting more than two million US citizens, and is a consequence of the substantial use of Rx-opioids for moderate and severe pain conditions in US as well as the widespread non-medical use of Rx-opioids. The earlier submission is expected to be of major commercial importance, as it provides a potential launch of Zubsolv in the third quarter of 2013 – ahead of other branded competitors.
With the NDA submission completed, Orexo’s CEO, Anders Lundström will provide company insights related to the specific market dynamics, which Zubsolv will be competing in. In addition, the company will present details of the continued development activities for the product, which have been designed and are being implemented. The primary objectives of these activities are to achieve a clear differentiation and prescriber understanding for the attributes that Zubsolv present, and to leverage the products competitive advantages in the US market place.
The presentation will be posted at Orexos homepage, www.orexo.com, following the meeting.
For further information, please contact:
Anders Lundström, President and CEO
Tel: +46 706-67 22 66, E-mail: firstname.lastname@example.org
Beata Augenblick, Investor Relations
Tel: +46 706-22 59 93, Email: email@example.com
Orexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating EU and US approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For more information about Orexo, please visit www.orexo.com
|Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 11:30am CET on September 17, 2012.|